inclusion criteria: 1. written informed consent of a subject to participate in the trial 2. males and females aged ≥18 y.o.; 3. negative hiv, hepatitis, and syphilis test results 4. negative anti-sars cov2 igm and igg antibodies test carried out with the enzyme immunoassay method 5. negative covid-2019 pcr test result at the screening visit 6. no covid-2019 in the past medical history 7. no contact with covid-2019 diseased persons within at least 14 days before the enrollment (according to trial subjects) 8. consent to use effective contraception methods during the trial 9. negative urine pregnancy test at the screening visit (for child-bearing age women) 10. negative drugs or psychostimulants urine test at the screening visit 11. negative alcohol test at the screening visit 12. no evident vaccine-induced reactions or complications after receiving immunobiological products in the past medical history 13. no acute infectious and/or respiratory diseases within at least 14 days before the enrollment.

inclusion criteria: 1. written informed consent of a subject to participate in the trial 2. males and females aged ≥18 y.o.; 3. negative hiv, hepatitis, and syphilis test results 4. negative anti-sars cov2 igm and igg antibodies test carried out with the enzyme immunoassay method 5. negative covid-2019 pcr test result at the screening visit 6. no covid-2019 in the past medical history 7. no contact with covid-2019 diseased persons within at least 14 days before the enrollment (according to trial subjects) 8. consent to use effective contraception methods during the trial 9. negative urine pregnancy test at the screening visit (for child-bearing age women) 10. negative drugs or psychostimulants urine test at the screening visit 11. negative alcohol test at the screening visit 12. no evident vaccine-induced reactions or complications after receiving immunobiological products in the past medical history 13. no acute infectious and/or respiratory diseases within at least 14 days before the enrollment.

inclusion criteria: written informed consent of a subject to participate in the trial males and females aged ≥18 y.o.; negative hiv, hepatitis, and syphilis test results negative anti-sars cov2 igm and igg antibodies test carried out with the enzyme immunoassay method negative covid-2019 pcr test result at the screening visit no covid-2019 in the past medical history no contact with covid-2019 diseased persons within at least 14 days before the enrollment (according to trial subjects) consent to use effective contraception methods during the trial negative urine pregnancy test at the screening visit (for child-bearing age women) negative drugs or psychostimulants urine test at the screening visit negative alcohol test at the screening visit no evident vaccine-induced reactions or complications after receiving immunobiological products in the past medical history no acute infectious and/or respiratory diseases within at least 14 days before the enrollment.

inclusion criteria: written informed consent of a subject to participate in the trial males and females aged ≥18 y.o.; negative hiv, hepatitis, and syphilis test results negative anti-sars cov2 igm and igg antibodies test carried out with the enzyme immunoassay method negative covid-2019 pcr test result at the screening visit no covid-2019 in the past medical history no contact with covid-2019 diseased persons within at least 14 days before the enrollment (according to trial subjects) consent to use effective contraception methods during the trial negative urine pregnancy test at the screening visit (for child-bearing age women) negative drugs or psychostimulants urine test at the screening visit negative alcohol test at the screening visit no evident vaccine-induced reactions or complications after receiving immunobiological products in the past medical history no acute infectious and/or respiratory diseases within at least 14 days before the enrollment.

inclusion criteria: 1. written informed consent of a subject to participate in the trial 2. males and females aged ≥18 y.o.; 3. negative hiv, hepatitis, and syphilis test results 4. negative anti-sars cov2 igm and igg antibodies test carried out with the enzyme immunoassay method 5. negative covid-2019 pcr test result at the screening visit 6. no covid-2019 in the past medical history 7. no contact with covid-2019 diseased persons within at least 14 days before the enrollment (according to trial subjects) 8. consent to use effective contraception methods during the trial 9. negative urine pregnancy test at the screening visit (for child-bearing age women) 10. negative drugs or psychostimulants urine test at the screening visit 11. negative alcohol test at the screening visit 12. no evident vaccine-induced reactions or complications after receiving immunobiological products in the past medical history 13. no acute infectious and/or respiratory diseases within at least 14 days before the enrollment.

inclusion criteria: 1. written informed consent of a subject to participate in the trial 2. males and females aged ≥18 y.o.; 3. negative hiv, hepatitis, and syphilis test results 4. negative anti-sars cov2 igm and igg antibodies test carried out with the enzyme immunoassay method 5. negative covid-2019 pcr test result at the screening visit 6. no covid-2019 in the past medical history 7. no contact with covid-2019 diseased persons within at least 14 days before the enrollment (according to trial subjects) 8. consent to use effective contraception methods during the trial 9. negative urine pregnancy test at the screening visit (for child-bearing age women) 10. negative drugs or psychostimulants urine test at the screening visit 11. negative alcohol test at the screening visit 12. no evident vaccine-induced reactions or complications after receiving immunobiological products in the past medical history 13. no acute infectious and/or respiratory diseases within at least 14 days before the enrollment.